iRay Group (SHA:688301)
China
· Delayed Price · Currency is CNY 120.25
-6.32 (-4.99%)
At close: Mar 9, 2026
iRay Group Revenue
In the year 2025, iRay Group had annual revenue of 2.30B CNY with 25.53% growth. iRay Group had revenue of 749.88M in the quarter ending December 31, 2025, with 57.80% growth.
Revenue
2.30B
Revenue Growth
+25.53%
P/S Ratio
11.63
Revenue / Employee
1.12M
Employees
2,093
Market Cap
26.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.30B | 467.54M | 25.53% |
| Dec 31, 2024 | 1.83B | -32.39M | -1.74% |
| Dec 31, 2023 | 1.86B | 314.67M | 20.31% |
| Dec 31, 2022 | 1.55B | 361.76M | 30.47% |
| Dec 31, 2021 | 1.19B | 403.27M | 51.43% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhende Medical | 4.32B |
| Intco Medical Technology | 9.85B |
| Andon Health | 1.57B |
| Winner Medical | 10.80B |
| Gan & Lee Pharmaceuticals. | 3.85B |
| Shenyang Xingqi Pharmaceutical | 2.41B |
| Imeik Technology Development | 2.52B |
| Jiangsu Hualan New Pharmaceutical Material | 604.86M |